Provided by Tiger Trade Technology Pte. Ltd.

Rapport Therapeutics, Inc.

48.69
+0.13000.27%
Volume:294.75K
Turnover:14.35M
Market Cap:2.34B
PE:-15.95
High:50.34
Open:48.50
Low:47.73
Close:48.56
52wk High:52.93
52wk Low:14.11
Shares:47.98M
Float Shares:30.39M
Volume Ratio:1.08
T/O Rate:0.97%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.0525
EPS(LYR):-2.8633
ROE:-39.96%
ROA:-25.78%
PB:5.52
PE(LYR):-17.00

Loading ...

Stock Track | Rapport Therapeutics Soars 5.20% Intraday on Wells Fargo Target Price Hike and Analyst Optimism

Stock Track
·
Mar 11

Rapport Therapeutics files automatic mixed securities shelf

TIPRANKS
·
Mar 10

Rapport Therapeutics : Files for Mixed Shelf Offering, Size Not Disclosed- SEC Filing

THOMSON REUTERS
·
Mar 10

Rapport Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 10

Rapport Therapeutics Q4 Loss Widens

MT Newswires Live
·
Mar 10

Rapport Therapeutics Q4 EPS $(0.72) Misses $(0.69) Estimate

Benzinga Earnings
·
Mar 10

Earnings Flash (RAPP) Rapport Therapeutics Posts Q4 Net Loss $0.72 a Share, vs. FactSet Est of $0.70 Loss

MT Newswires Live
·
Mar 10

Press Release: Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Mar 10

Analysts Are Bullish on These Healthcare Stocks: Rapport Therapeutics, Inc. (RAPP), Jazz Pharmaceuticals (JAZZ)

TIPRANKS
·
Mar 10

BUZZ-U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow

Reuters
·
Mar 09

BUZZ-U.S. STOCKS ON THE MOVE-Hims & Hers, Live Nation, NovaBridge

Reuters
·
Mar 09

BUZZ-Rapport Therapeutics rises on granting China rights for epilepsy drug

Reuters
·
Mar 09

Rapport Therapeutics Shares up 4.3% Premarket as It Grants China Rights for Epilepsy Drug

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - to Receive $20 Mln Upfront, up to $308 Mln in Milestones, and Tiered Royalties

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - Tenacia Obtains Exclusive Rights to Develop and Commercialize Rap-219 in Greater China

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics Inc - Phase 3 Program for Rap-219 Expected to Start in Q2 2026 With Trial Sites in China

THOMSON REUTERS
·
Mar 09

Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China

GlobeNewswire
·
Mar 09